Wakefield, MA – According to filings with the U.S. Securities and Exchange Commission, Ablative Solutions is raising $91,462,993.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Kate Rumrill played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ablative Solutions

Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea. The Peregrine System Infusion Catheter provides physicians with a way to infuse diagnostic and therapeutic agents into the area surrounding the renal artery, where sympathetic nerves are located. The Company is in the process of initiating two randomized sham-controlled trials using the Peregrine System Kit, which includes the Peregrine Catheter and Ablative Solutions dehydrated alcohol, for the treatment of hypertension with chemical renal denervation.

To learn more about Ablative Solutions, visit http://ablativesolutions.com/

Contact:
Kate Rumrill, President and Chief Executive Officer
650-688-9743
https://www.linkedin.com/in/krumrill/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved